Company: DMAAR
Filing Date: 2025-11-18
Form Type: 10-Q
Source: 0001213900-25-112096
Chunk: 69

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-11-18
Form: 10-Q
Item: Part I, Item 8
Chunk 69
---
emeasurement
    of carrying value to redemption value 
        
     2,924,356 
  
    Ordinary
    shares subject to possible redemption, March 31, 2025 
     23,000,000  
    $232,735,468 
  
    Plus: 

    Remeasurement
    of carrying value to redemption value 
        
     2,420,498 
  
    Ordinary
    shares subject to possible redemption, June 30, 2025 
     23,000,000  
    $235,155,966 
  
    Plus: 

    Remeasurement
    of carrying value to redemption value 
        
     2,448,266 
  
    Ordinary
    shares subject to possible redemption, September 30, 2025 
     23,000,000  
    $237,604,232 

Derivative
Financial Instruments

The
Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded
derivatives in accordance with ASC Topic 815, “Derivatives and Hedging”. For derivative financial instruments that are
accounted for as liabilities, the derivative instrument is initially recorded at its fair value on the grant date and is then re-valued
at each reporting date, with changes in the fair value reported in the statement of operations. The classification of derivative instruments,
including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period.
Derivative liabilities are classified in the unaudited balance sheets as current or non-current based on whether or not net cash settlement
or conversion of the instrument could be required within 12 months of the unaudited balance sheets date. The underwriters’
over-allotment option is deemed to be a freestanding financial instrument indexed on the contingently redeemable shares and was accounted
for as a liability pursuant to ASC 480 since it was not exercised at the time of the Initial Public Offering.

10

DRUGS
MADE IN AMERICA ACQUISITION CORP.

NOTES
TO FINANCIAL STATEMENTS

SEPTEMBER
30, 2025

(Unaudited)

Net
Income (Loss) Per Ordinary Share

The
Company complies with accounting and disclosure requirements of FASB ASC Topic 260, “Earnings Per Share.” The Company has
two classes of ordinary shares, which are referred to